Michael Katwere

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Zacchaeus Anywaine, Houreratou Barry, Omu Anzala et al. · PLoS Medicine · 2022 · 63 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Vaccine value profile for Klebsiella pneumoniae

Ziyaad Dangor, Nicole M. Benson, James A. Berkley et al. · Vaccine · 2024 · 62 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Pharmacy, Infectious Disease Control, Pharmacotherapy +17

The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.

Ponsiano Ocama, Michael Katwere, Theresa Piloya et al. · PubMed · 2008 · 39 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

Julien Nyombayire, Rosine Ingabire, Ben Magod et al. · The Journal of Infectious Diseases · 2022 · 28 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +17